scholarly journals EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C

2017 ◽  
Vol 18 (3) ◽  
pp. 144-151 ◽  
Author(s):  
M Asnavandi ◽  
M Zargar ◽  
F Vaziri ◽  
F R Jamnani ◽  
S Gharibzadeh ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Treatment Responses ◽  
Iranian Patients

Evaluation of TRIM5 and TRIM22 polymorphisms on treatment responses in Iranian patients with chronic hepatitis C virus infection

Gene ◽  
2018 ◽  
Vol 676 ◽  
pp. 95-100 ◽  
Author(s):  
Setareh Mobasheri ◽  
Nazanin Irani ◽  
Abbas Akhavan Sepahi ◽  
Fatemeh Sakhaee ◽  
Fatemeh Rahimi Jamnani ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Chronic Hepatitis C ◽  
Hepatitis C Virus Infection ◽  
Chronic Hepatitis C Virus ◽  
Treatment Responses ◽  
Iranian Patients

scholarly journals Early Prediction of Nonresponders to Treatment with Interferon Alpha-2B and Ribavirin in Patients with Chronic Hepatitis C

2003 ◽  
Vol 17 (8) ◽  
pp. 483-487 ◽  
Author(s):  
Louis WC Liu ◽  
George Tomlinson ◽  
Tony Mazzulli ◽  
Alison Murray ◽  
Jenny Heathcote
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Interferon Alpha ◽  
Baseline Viral Load ◽  
Hcv Rna ◽  
Interferon Alpha 2B ◽  
Quantitative Measurements ◽  
Treatment Responses

BACKGROUND: Treatment of chronic hepatitis C virus (HCV) infection with interferon alpha-2b and ribavirin is costly in terms of side effects, medical resources and drug costs. Furthermore, less than 50% of patients overall have a sustained virological response (SVR).OBJECTIVE: To determine if the log fall in HCV RNA between baseline and week 1 (b-wk1) and between baseline and week 4 (b-wk4) after starting treatment could identify the nonresponders.PATIENTS AND METHODS: Sixty-three patients who had completed a full course of therapy were identified. Quantitative measurements of HCV RNA were analyzed from stored sera, collected prospectively.RESULTS: SVR was achieved in 47.1% and 47.3% of patients in the b-wk1 and b-wk4 groups, respectively. No patients had an SVR with a fall in HCV RNA of less than 0.35 log10and 1.05 log10at week 1 and week 4, respectively. This accounted for 44.4% and 51.7% of the nonresponders in the b-wk1 and b-wk4 groups, respectively. Once the decline in viral load was known, genotype, age, sex and baseline viral load did not provide additional power in predicting treatment responses.CONCLUSION: A fall of 1.05 log10in HCV RNA at week 4 predicts those patients who will not respond, identifying one-half of all nonresponders; this allows therapy to be stopped early, without depriving any patient who would have an SVR from treatment.

Investigation of Transforming Growth Factor-β1 Gene Polymorphisms Among Iranian Patients With Chronic Hepatitis C

2011 ◽  
Vol 11 (11) ◽  
pp. 901-906 ◽  
Author(s):  
Sara Romani ◽  
Pedram Azimzadeh ◽  
Seyed Reza Mohebbi ◽  
Shabnam Kazemian ◽  
Shohreh Almasi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Growth Factor ◽  
Chronic Hepatitis C ◽  
Gene Polymorphisms ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β1 ◽  
Iranian Patients

Viral and Host Factors Associated with Steatosis in Iranian Patients with Chronic Hepatitis C

2006 ◽  
Vol 101 ◽  
pp. S166-S167
Author(s):  
Mohammad Minakari ◽  
Mohammadreza Zali ◽  
Farzaneh Khademsameni ◽  
Hamid Mohagheghshalmani
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Host Factors ◽  
Factors Associated ◽  
Iranian Patients

scholarly journals The Impact of Interleukin-28B rs12979860 Polymorphism on Peginterferon-alpha and Ribavirin Combination Therapy in Iranian Patients with Hepatitis C Virus Genotype 1 Infection

2017 ◽  
Vol 1 (1) ◽  
Author(s):  
Mahboubeh Hajiabdolbaghi ◽  
Reza Shahsiah ◽  
Mahsa Motavaf ◽  
Tabasom Zavari
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Treatment Response ◽  
Chronic Hepatitis C ◽  
Hcv Infection ◽  
Genotype 1 ◽  
Interleukin 28B ◽  
Iranian Patients

Background: Hepatitis C virus (HCV) infection is a global health problem. Most cases of HCV infection do not resolve spontaneously. Combination therapy with pegylated interferon-α (PegIFN-alpha) and ribavirin (RBV) is the standard treatment for patients with HCV infection. The success of treatment is affected by several host, viral, and treatment factors. Available works have demonstrated significant role of interleukin 28B (IL28B) polymorphisms in predicting HCV infection treatment outcomes. This suggests the possibility of tailored therapy in HCV infected patients. HCV is one of the most common causes of liver disease worldwide. If untreated, this infection can develop chronic hepatitis in 50%-85% of patients. The aim of current study is to determine the association of interleukin-28B (IL-28B) rs-12979860 polymorphism in response to peginterferon-alpha (PegIFN-alpha) and ribavirin combination therapy in Iranian patients with chronic hepatitis C genotype 1 infection. Methods: This cross-sectional study was carried out on 70 Iranian patients with chronic hepatitis C infection (genotype 1) receiving PegIFN-alpha and ribavirin. DNA was extracted from blood samples. Specific primers were used to amplify targeted polymorphisms. Results: In this study, 71.4% of patients reached sustained virological response (SVR). The prevalence of CC, CT and TT genotypes were 38.6%, 42.8% and 18.6% respectively. The rate of SVR was 96.3 for CC genotype, whereas this rate was 66.7 for CT and 30.8 for TT genotypes. We found an association between end of treatment response (ETR) and IL-28B genotypes as 100% of patients bearing CC genotype reached ETR, but ETR rate was 45.85% in CT group and 10.2% in TT group. Six months follow-up showed that there was a significant difference between response to treatment in patients IL-28B-CC and TT (P < 0.001). Data regression analysis showed that CC genotype was an independent predicting factor, significantly associated with higher SVR (P = 0.005 (OR=36.1; 95% CI = 3 - 434.2)). In contrast, absence of C allele (TT genotype) was significantly correlated with the failure of response (P = 0.005 (OR = 36.1; 95% CI = 3 - 434.2)). Conclusions: The results showed that IL-28B rs12979860 was an important predictor of HCV treatment response.

Sign in / Sign up

Export Citation Format

Share Document